LETTERS FOR ISSUE ON

Similar documents
LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

TODAY LETTER DATED

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

LETTERS FOR ISSUE ON

THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES

LETTERS FOR ISSUE ON

File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division

US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health

Oncology Pipeline Analytics

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Organizational, or Other Financial Benefit None None None None None None. None None None None None None

CHAPTER ONE: EXECUTIVE SUMMARY

BRIC DIABETES DRUGS MARKET

Name of firm/applicant

John Ansell President, John Ansell Consultancy Thame, UK

Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division

Vascular Endothelial Growth Factor Inhibitor Market

Global Aspergillosis Drugs Market Professional Survey Report 2016

American Association for Cardiovascular and Pulmonary Rehabilitation (AACVPR)

THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd

10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE

3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.

Pancreatic Cancer Market Research Report- Global Forecast till 2023

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3

Global Coverage. Regional Coverage. Company Coverage. Country Coverage. Global Coverage Regional Coverage Country Coverage

CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA

Boston University Expert Review Meeting on the Evaluation of Novartis Access

Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast

CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...

Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-

J. C.-H. Yang 1, L.V. Sequist 2, S. L. Geater 3, C.-M. Tsai 4, T. Mok 5, M. H. Schuler 6, N. Yamamoto 7, D. Massey 8, V. Zazulina 8, Yi-Long Wu 9

Organ Transplantation Market Research Report- Global Forecast Till 2023

Influenza Vaccination Market Research Report Global Forecast till 2023

SickKids Research Institute: List of Funders

Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016

TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF

Iraq NDI Iraq 04-J India 05-AH France Famar Lyon France 05-D UNITED ARAB EMIRATES. Iraqi Biocon Limited Indian 06-AA0-001

Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B

Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry

Decision for fibrinolysis or primary PCI in the prehospital phase

(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)

New study: Tuberculosis vaccine treatment market research forecast to 20...

2014 DTC National Advertising Awards Finalists

Critical Pathways in Breast Cancer Treatment

in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017

SUNY Binghamton, B.S. Biochemistry, 5/80 SUNY Downstate Medical Center, M.D., 6/84

Karan Sharma. Phone: Availability: Fulltime. 4:00 AM to 9:00 PM (GMT) Language groups:

290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3

Cardiac Monitoring: Market and Outsourcing Dynamics. October, 2014

Quality Medical Donations

REFERENCE CODE GDHC1013FPR PUBLICAT ION DATE AUGUST 2013 MENINGOCOCCAL VACCINES - CURRENT AND FUTURE PLAYERS

Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines

The Crisis in. Vaccine Development

MEDICINES FOR SMOKING CESSATION: GLOBAL MARKETS. PHM154A September Anand Gijare Project Analyst ISBN:

How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin

Type 1 Diabetes (T1D) Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

RESULTS AND DISCUSSION

Addressing the challenges of diabetes and its complications: The IMI Diabetes Platform

Cardiac Bone Marrow Cell Injection for Chronic Ischemic Heart Disease

GLOBAL MARKETS FOR DIABETES THERAPEUTICS AND DIAGNOSTICS

Industry Relationships and Institutional Affiliations

Presenter Disclosure

Development of Novel Anti-Calcineurin Drugs for the

Merrill Lynch Global Healthcare Conference February 4, Shire Pharmaceuticals Group plc

Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany

Glenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;

75th AAD Annual Meeting

The 22nd SEC (Oncology& hematology) meeting deliberated the proposals on and recommended the following:- volunteers.

THYROID HORMONE THERAPY TABLE 21 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR FIGURE 4 SHARES OF MANUFACTURERS/DISTRIBUTORS FOR

Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism

INCRETIN-BASED DRUGS: MARKETS FOR DIABETES THERAPIES AND DEVELOPING TREATMENTS

Name of firm/applicant. Torrent Pharmaceuticals. Glenmark Pharmaceuticals. M/s. Torrent Pharmaceutical. Torrent Pharmaceuticals

Country Coverage. Company Coverage

Dear Representative Burgess, Representative DeGette, Senator King, Senator Crapo, and Senator Cardin:

BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS

The Role of Pharmaceutical Industry in Vaccine R&D

Detailed cost of vaccination/ Immunization in India (Birth to 10 years of age)

Stroke and Headache Headache and Stroke

ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)

TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage

Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects on Remnant-like Particle Cholesterol From the MARINE and ANCHOR Studies

Global Vitamin Market Professional Survey Report 2016

Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer

New Prognostic Markers in Acute Myeloid Leukemia (AML)

ANTITHROMBOTIC/ANTICOAGULANT DRUGS: TECHNOLOGIES AND GLOBAL MARKETS

Transcription:

S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S. ELI LILLY ASIA INC. - QUERY MEDICAL DEVICE S. COMPANY NAME DIARY NO STATUS 1. M/S. PAUL HARTMANN MEDICAL PVT. LTD. 9108 APPROVAL (R-RC) 2. M/S. GENOME DIAGNOSTICS PVT. LTD. NIL DIAGNOSTICS DIVISION S. COMPANY NAME DIARY NO STATUS 1. M/S. SAIFY TRADERS 18349 APPROVAL (IL) 2. M/S. SIEMENS LIMITED NIL 3. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD. NIL VACCINE DIVISION S. COMPANY NAME DY. NO STATUS 1 M/S WOCKHARDT LTD 23593, 40300 (FTS NO) CLARIFICATION 2 M/S JOHNSON & JOHNSON LTD 26144 CLARIFICATION

3 M/S SANZYME 22537 CLARIFICATION 4 M/S NOVARTIS HEALTHCARE 5 M/S BHARAT BIOTECH INTERNATIONAL LTD 23971 CLARIFICATION 22937 CLARIFICATION 6 M/S BIOCON LTD CLARIFICATION 7 M/S BIOMED 25409 CLARIFICATION 8 M/S SANOFI SYNTHELABO INDIA LTD CLARIFICATION 9 M/S BIOCON LTD 17824 CLARIFICATION 10 M/S VITA PHARMA AGENCIES 25613 CLARIFICATION 11 M/S LG LIFE SCIENCES INDIA 12 M/S NOVO MEDI SCIENCES 24893 CLARIFICATION 27460 CONTINUATION GLOBAL CLINICAL TRIAL SR. NAME OF FIRM REFERENCE TYPE OF 1. M/S. PFIZER 15678 NEW SITE 2. M/S. MAX NEEMAN 23995 CLARIFICATION 3. M/S. NOVARTIS 25270/26012/24241/2642/25270 TL/ CLARIFICATION 4. M/S. AMGEN 25462 CORRECTION IN APPROVAL 5. M/S. GEORGE CLINICAL INDIA 24566 CLARIFICATION 6. M/S. PPD 25376 AMENDMENT IN EXPORT NOC APPROVAL 7. M/S. QUINTILES 25375 TL APPROVAL

8. M/S. BOEHRINGER 26092/27037 CHANGE IN PI / TL APPROVAL MEDICAL DEVICE S. COMPANY NAME DIARY NO STATUS 3. M/S. BAXTER (INDIA) PVT. LTD. 18700 QUERY 4. M/S. BOSTON SCIENTIFIC INDIA PVT. LTD. 18734 5. M/S. BOSTON SCIENTIFIC INDIA PVT. LTD. 13537 QUERY 6. M/S. CLAIRVOYANCE CONSULTING 18512 7. M/S. JOHNSON & JOHNSON PVT. LTD. 22612 8. M/S. JOHNSON & JOHNSON PVT. LTD. 17118 QUERY 9. M/S. JOHNSON & JOHNSON PVT. LTD. 21306 QUERY 10. M/S. JOHNSON & JOHNSON PVT. LTD. 9821 QUERY 11. M/S. LIFECELL INTERNATIONAL PVT. LTD. 20799 12. M/S. MN SOLUTIONS 12601 QUERY 13. M/S. ST. JUDE MEDICAL INDIA PVT. LTD. 10202 QUERY 14. M/S. SKINCARE SURGIPHARMA PVT. LTD. 21887 QUERY 15. M/S. ZIMMER INDIA PVT. LTD. 16222 QUERY 16. M/S. ZIMMER INDIA PVT. LTD. 16240 QUERY 17. ALL PORT OFFICE OF CDSCO DDC (I) OF ALL ZONAL OFFICES OF CDSCO ( OFFICE MEMORANDUM - RECALL OF EXTRACTOR PRO RX RETRIEVAL BALLOON CATHETER ) 18. M/S. PAUL HARTMANN MEDICAL PVT. LTD. 9108 APPROVAL (R-RC) 19. M/S. GENOME DIAGNOSTICS PVT. LTD. NIL

DIAGNOSTICS DIVISION S. COMPANY NAME DIARY NO STATUS 4. M/S. BJMC CRS 35443 QUERY 5. M/S. QUALPRO DIAGNOSTICS C/O VIOLA DIAGNOSTICS SYSTEMS 24327 QUERY 6. M/S. IRIS HEALTHCARE TECHNOLOGIES PVT. LTD. 23698 QUERY 7. M/S. SAIFY TRADERS 18349 APPROVAL (IL) 8. M/S. SIEMENS LIMITED NIL 9. M/S. ROCHE DIAGNOSTICS INDIA PVT. LTD. NIL REGISTRATION S. NAME OF APPLICANT DIARY TYPE OF 1. ESSCHEM PVT. LTD. 22450 APPROVAL 2. SYMBIO GENERICS INDIA PVT. LTD. NIL APPROVAL 3. ALLIED PHARMA SOLUTION 24260 APPROVAL 4. UNICHEMIE INERNATIONAL 13258,13036 02 AMENDMENT 5. LASCO INTERNATIONAL 17448 ` AMENDMENT 6. JOHNSON & JOHNSON 5547 7. GSK ASIA PVT. LTD. 8. EISAI PHARMACEUTICALS INDIA 17832 CLARIFICATION PVT. LTD. 9. RUSHI CORPORATION 17924 CLARIFICATION 10. EASTERN CHEMICAL (MUMBAI) 17959 CLARIFICATION PVT. LTD. 11. RUSKIN CHEMIPHARM 23834 CLARIFICATION 12. ASTRAZENECA PHARMA INDIA LTD. 25168 CLARIFICATION 13. SHIVAM PHARMA CHEMICALS 25114 CLARIFICATION 14. FORMACHEM LIFE PVT. LTD. 21715,19122 02 CLARIFICATION